Navigation Links
Boehringer Ingelheim's interferon-free hepatitis C treatment portfolio strengthened by promising interim Phase 2a data
Date:11/2/2013

PegIFN/RBV. The four trials that make up this program study the combination in treatment-naive, treatment-experienced and HIV/HCV coinfected patients with chronic genotype-1 HCV. Deleobuvir (BI 207127) is an investigational NS5B non-nucleoside polymerase inhibitor that has shown the potential to eliminate interferon from HCV treatment when combined in a regimen with faldaprevir and RBV. Phase 2 trials of this interferon-free regimen have been completed and Phase 3 HCVerso® trials investigating this regimen are now underway. As part of our long-term commitment to HCV, the company is exploring other combinations of investigational HCV compounds that work in complementary ways. The recent collaboration of Boehringer Ingelheim with Presidio Pharmaceuticals, Inc. for a Phase 2a clinical study investigating an interferon- and ribavirin-free, all-oral combination is part of the company's continued commitment to discover and develop innovative options for the treatment of HCV.

STARTVerso™ and HCVerso® are registered service marks of Boehringer Ingelheim International GmbH.

Hepatitis C is a blood-borne infectious disease and a leading cause of chronic liver disease, transplant and failure that affects as many as 150 million people globally. In the United States, approximately 3.2-5.2 million people have chronic HCV infection. Since 1999 there has been a significant increase in deaths due to chronic HCV, which accounts for 10,000 -12,000 deaths in the United States per year.

About Boehringer Ingelheim
Boehringer Ingelheim Pharmaceuticals, Inc., based in Ridgefield, CT, is the largest U.S. subsidiary of Boehringer Ingelheim Corporation (Ridgefield, CT) and a member of the Boehringer Ingelheim group of companies.

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical compa
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Boehringer Ingelheim Announces Launch of GLORIA™-AF Registry in Newly-Diagnosed Patients with Non-Valvular Atrial Fibrillation
2. New Data to be Presented at the Annual American Thoracic Society International Conference Demonstrates Depth of Boehringer Ingelheim Respiratory Research Pipeline
3. Boehringer Ingelheim to present pivotal Phase III results for afatinib in first-line treatment of EGFR mutation-positive NSCLC at ASCO 2012
4. Results of Phase II Study of Boehringer Ingelheims Investigational Bronchodilator for COPD Presented at 2012 ATS International Conference
5. Boehringer Ingelheim Presents First Data for Tiotropium in Adolescents with Moderate Persistent Asthma
6. Lilly and Boehringer Ingelheim Present Data at the 72nd American Diabetes Association Scientific Sessions® from Phase II Studies Comparing Investigational Novel Basal Insulin to Insulin Glargine
7. Boehringer Ingelheim and Lilly introduce the My Well Planner Lifestyle Improvement Program for Adults with Type 2 Diabetes
8. Boehringer Ingelheim announces afatinib expanded access program (EAP) for patients with EGFR mutation-positive advanced NSCLC
9. Whistleblowers extraordinary efforts helped win $95 million settlement with Boehringer Ingelheim
10. Phase 2b Data of Boehringer Ingelheims Interferon-Free Hepatitis C Treatment Show Viral Cure Achieved in Up to 85% of Treatment-Naive Patients
11. Boehringer Ingelheim Announces Equine Research Awards
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... AUSTIN, Texas , Jan. 14, 2014  Luminex Corporation (Nasdaq: ... report results for the fourth quarter of 2013 on Monday, ... scheduled for release after the close of trading. ... a conference call to discuss the operating highlights and financial ...
(Date:1/14/2014)... 14, 2014 Dynamic Healthcare Services, Inc. ("DHS"), a portfolio ... acquired Progressive Home Medical Equipment, Inc. ("Progressive") of ... of the acquisition were not disclosed. Progressive ... a wide range of sleep, mobility, and respiratory products to ...
(Date:1/14/2014)... 14, 2014   NuAire , a manufacturer of ergonomically designed ... Hitachi Koki of Japan to sell ... America . NuAire will utilize its network of sales professionals ... Canada to offer assistance in application use, product benefits ...
Breaking Medicine Technology:Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3NuAire announces sales and service of Hitachi Koki centrifuges in North America 2
... (OMX Nordic: ACTI) presented,pre-clinical results for the ... League Against Rheumatism, <a target="_blank" href=,"http://www.eular.org/">www.eular.org ... data presented show that I-3D has a,significant ... model for rheumatoid arthritis (RA)", commented Sven,Andréasson, ...
... /PRNewswire/ -- Solstice,Neurosciences, Inc. today reported important results ... Toxin Type B,Injectable Solution (Myobloc(R)) recently presented at ... in,Istanbul, Turkey. , This was the first multicenter ... treatment doses of 10,000 Units, 12,500,Units, and 15,000 ...
Cached Medicine Technology:New Positive Pre-clinical Data for Active Biotech's RA Project I-3D 2Solstice Neurosciences Presents Escalating Dose Study at,International Congress in Istanbul, Turkey 2Solstice Neurosciences Presents Escalating Dose Study at,International Congress in Istanbul, Turkey 3Solstice Neurosciences Presents Escalating Dose Study at,International Congress in Istanbul, Turkey 4
(Date:7/9/2014)... Cincinnati, OH, July 10, 2014 -- The World Health ... 60 minutes of moderate to vigorous physical activity (MVPA) ... most of their MVPA during school hours. Therefore, ... school hours would increase MVPA. In a new ... Pediatrics , researchers confirmed that time spent outdoors after ...
(Date:7/9/2014)... Researchers at the Perelman School of Medicine at ... Park Cancer Institute have received an $8 million grant ... effects of photodynamic light therapy (PDT) in patients with ... that most often manifests itself in the lining of ... to asbestos. The grant will fund a clinical trial ...
(Date:7/9/2014)... lung cancer, researchers have uncovered mutations in a cell-signaling ... new knowledge may expand treatments for patients because drugs ... or are in clinical trials. , Reporting July 9 ... Atlas (TCGA), including researchers at Washington University School of ... institutions, studied tumors from 230 patients with lung adenocarcinoma. ...
(Date:7/9/2014)... users in Russia might contribute to HIV transmission ... by researchers from Boston University Schools of Medicine ... Pavlov State University, sought to discover the effect ... a cohort of HIV-positive people with lifetime of ... by police were more likely to share needlesincreasing ...
(Date:7/9/2014)... 2014 There has been a sharp increase in ... Center using MyChart, the online, interactive service that allows ... their healthcare providers, schedule appointments, and renew prescriptions. , ... using MyChart each year increased five-fold, while ... than 10-fold, according to a study by Dr. ...
Breaking Medicine News(10 mins):Health News:Go play outside! Outdoor time promotes physical activity in youth 2Health News:Penn mesothelioma program receives $8 million NCI grant 2Health News:Lung cancer study hints at new treatments 2Health News:BU researchers relate arrests with HIV risk environment 2Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 2Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 3
... are being led to believe that, if they get ... it a ‘vaccine;’ but it is not a vaccine// ... under false pretenses. ,“The century-old circumcision ‘experiment’ ... sub-Saharan Africa be any different?” asks Dan Bollinger, director ...
... British Hindus and Sikhs to be allowed to hold open-air ... with a charity //fighting for the cause being allowed to ... of the Anglo Asian Friendship Society, has been given permission ... judge, Justice Andrew Collins. ,The development follows a ...
... in soil boosts happiness levels and could help restore healthy ... infection, says a study. ,British scientists led by ... the bacteria, named 'bacterium Mycobacterium vaccae', and found improvement in ... News. ,However, they said more work is needed ...
... testosterone, which plays a key role in health and ... ,People suffering with Alzheimer's lack the ability to ... As the disease progresses, individuals may also experience changes ... agitation, as well as delusions or hallucinations. ...
... Limited has achieved a significant milestone in its ... Drug Discovery Research (NDDR) team has finished the ... ,As per the recently signed multi-year ... Ranbaxy will further profile this drug candidate through ...
... end to the problems caused by obesity. Like magicians pulling rabbits ... another caused by failure to control one’s weight. // ,The ... small tubes - airways - that carry air in and out ... higher risk of developing asthma, US researchers have concluded after reviewing ...
Cached Medicine News:Health News:Promoting Circumcision to Prevent HIV is Misguided and Will Backfire: ICGI 2Health News:Obesity can Cause Asthma too 2
The Model 340DT is a new desk top pulse oximeter that was designed for continuous pulse oximetry and has visual and audible alarms to aid with patient monitoring....
The Model 305 is a hand-held, portable, lightweight oximeter designed for spot checking. It has a NiCad rechargeable battery....
... The Model 130 has expanded memory capabilities ... has memory to retain oxygen saturation and pulse ... modes to best suit your needs:, ,1. ... minutes of information for a single patient, making ...
... into comfortable holder, measuring switch is ... is performed., ,Large display of ... surroundings, back light automatically turns on ... compact contour and design provide steady, ...
Medicine Products: